Eli Lilly Stock Surges 7%, Adding $77 Billion, As Mounjaro Sales Jump 65% And Revenue Outlook Rises

Shares hit a 52-week high after Lilly raised its 2026 sales forecast, though deal charges trimmed its adjusted profit outlook.

Share
Eli Lilly Stock Surges 7%, Adding $77 Billion, As Mounjaro Sales Jump 65% And Revenue Outlook Rises

Eli Lilly, the drugmaker behind the diabetes and obesity treatments Mounjaro and Zepbound, saw its shares climb 6.67% to $1374.29 in Thursday trading as of 10:49 a.m. ET, adding $77 billion in market value, after it reported third-quarter revenue of $24.4 billion and raised its full-year sales forecast for the third time this year.

A $5.5 billion bump to the forecast

Lilly raised its 2026 revenue forecast to $91 billion to $92 billion, from $85 billion to $87 billion. That is $5.5 billion higher at the midpoint.

Mounjaro sales jumped 65% to $10.72 billion in the third quarter. Zepbound sales reached $5.35 billion, up 49% from a year earlier, CNBC reported.

Foundayo, Lilly's weight-loss pill, generated $184 million in third-quarter sales, short of the roughly $229 million analysts expected, according to CNBC.

Deal charges trim the profit outlook

Lilly now projects 2026 adjusted earnings of $35 to $36 a share, below the prior $35.50 to $36.50. The company said $4.57 a share in deal-related research charges offset a $4.07 underlying increase.

A record run for the stock

The shares touched a new 52-week high of $1374.29 on Thursday and were on pace for their biggest one-day gain since June 26, when they rose 7.1%.

They were already up about 20% year to date at Wednesday's close, against about 13% for the S&P 500. They had been within 2% of their highest close of the past year, set October 22, and were heading for a fourth straight daily gain.

Lilly develops, manufactures and markets human pharmaceuticals as a single business. Its lineup spans diabetes and obesity, cancer, immune and neurological conditions. In the prior reported quarter, it posted revenue of $23 billion, up 47.7% from a year earlier, with net income of $7.1 billion.

Thursday's quarter put Lilly's full-year revenue guidance at $91 billion to $92 billion, with Mounjaro and Zepbound together bringing in more than $16 billion in the third quarter alone.

Sources

More on Eli Lilly and

All Eli Lilly and (LLY) coverage →